GlassScriptPhysician profile
Andrew H Selinger
NPI 1114937141
$3,309.35
in general payments reported to CMS, 2019-2025
27 companies · $614 in 2025
The $614 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2021: $221 · 2022: $447 · 2023: $1,068 · 2024: $789 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,217 · Consulting Fee: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,216.62 |
| Consulting Fee | $254.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $548.65 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $514.16 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Radiometer America, INC | $425.00 | 2019-2025 | |
| Abbvie INC. | $312.37 | 2021-2025 | Vraylar |
| Sanofi-Aventis U.S. LLC | $166.28 | 2021-2023 | |
| Exact Sciences Corporation | $145.75 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $128.32 | 2022-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $124.02 | 2023-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $120.39 | 2021-2025 | Breztri |
| E.R. Squibb & Sons, L.L.C. | $113.38 | 2021-2023 | Eliquis |
| Pfizer INC. | $108.80 | 2021-2025 | |
| Glaxosmithkline, LLC. | $90.81 | 2022-2023 | Trelegy Ellipta, Shingrix, Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.40 | 2021-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $74.03 | 2022-2025 | Gardasil 9, Dificid, Capvaxive |
| Actelion Pharmaceuticals US, INC. | $66.10 | 2024-2025 | Uptravi, Opsumit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $53.27 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $45.78 | 2022-2023 | Seglentis |
| Sanofi Pasteur INC. | $45.52 | 2024 | |
| Amarin Pharma, INC. | $24.88 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.68 | 2024 | Caplyta |
| Abbott Laboratories | $21.45 | 2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.06 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $17.67 | 2021 | |
| Lifescan, INC. | $14.84 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.77 | 2023 | Nuzyra |
| Organon LLC | $9.97 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Selinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.